European Commission Approves Olaparib Combinations for mCRPC

Article

Olaparib in combination with abiraterone and prednisone or prednisolone alone has been approved as treatment for metastatic castration-resistant prostate cancer in the European Union.

The European Commission has granted approval to olaparib (Lynparza) in combination with abiraterone acetate (Zytiga) and prednisone or prednisolone alone as treatment for adult patients with metastatic castration-resistant prostate cancer (mCRPC) for whom chemotherapy is not clinically indicated, according to a press release from AstraZeneca and Merck.1

The approval was supported by findings from the phase 3 PROpel trial (NCT03732820), which indicated that olaparib plus abiraterone and prednisone or prednisolone yielded a 34% reduction in risk of disease progression or death compared with placebo plus abiraterone (HR, 0.66; 95% CI, 0.54-0.81; P <.0001). Additionally, the median radiographic progression-free survival (rPFS) was 24.8 months (95% CI, 20.5-27.6) among patients receiving olaparib vs 16.6 months (95% CI, 13.9-19.2) for patients in the placebo cohort.

A planned sensitivity analysis by blinded independent central review highlighted a median rPFS of 27.6 months and 16.4 months in the olaparib and placebo arms, respectively. The secondary end point of overall survival in the PROpel trial was 37.1% in the olaparib arm vs 43.1% in the placebo arm, although statistical significance was not reached (HR, 0.83; 95% CI, 0.66-1.03).

“The results of the phase 3 PROpel trial of olaparib in combination with abiraterone as a first-line treatment show that this therapeutic combination can provide significant clinical benefit to patients with mCRPC,” Noel Clarke, MBBS, FRCS, ChM, senior investigator of the PROpel trial, urological surgeon, and professor of urological oncology at Manchester’s Christie/Salford Royal Hospitals and Manchester University, said in the press release. “Patients with this condition in the European Union will now, for the first time, have the opportunity to benefit from this new treatment combination.”

Previously, the FDA gave priority review to a supplemental application for olaparib plus abiraterone in mCRPC regardless of homologous recombination repair mutational status in August 2022.2 The regulatory decision was also based on findings from the phase 3 PROpel trial.

References

  1. LYNPARZA® (olaparib) in combination with abiraterone and prednisone or prednisolone approved in the EU as treatment for certain patients with metastatic castration-resistant prostate cancer. News release. AstraZeneca, Merck. December 21, 2022. Accessed December 21, 2022. bit.ly/3v6ghIy
  2. First PARP inhibitor to demonstrate clinical benefit in combination with a new hormonal agent irrespective of homologous recombination repair (HRR) gene mutations. AstraZeneca. News release. August 16, 2022. Accessed December 21, 2022. https://bit.ly/3C6uuKj
Related Videos
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Rana R. McKay, MD, presenting slides
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Related Content
Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.

European Commission Approves Enzalutamide in nmHSPC Subset

April 25th 2024
Article

Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

May 30th 2022
Podcast

Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.

A series of phase 3 findings support the European approval of tislelizumab as a first-line and second-line treatment for non–small cell lung cancer.

Tislelizumab Earns European Approval in Non–Small Cell Lung Cancer

April 23rd 2024
Article

A series of phase 3 findings support the European approval of tislelizumab as a first-line and second-line treatment for non–small cell lung cancer.

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer

April 26th 2022
Podcast

Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.

Toripalimab plus axitinib is now an approved regimen in China for patients with medium- to high-risk unresectable or metastatic renal cell carcinoma.

Toripalimab Combo Receives Chinese Approval for Advanced RCC

April 10th 2024
Article

Toripalimab plus axitinib is now an approved regimen in China for patients with medium- to high-risk unresectable or metastatic renal cell carcinoma.

Data from a phase 3b trial support a supplemental new drug application in China for savolitinib in previously treated non–small cell lung cancer with MET exon 14 alterations.

China Accepts sNDA for Savolitinib in Previously Treated MET Exon 14 NSCLC

April 6th 2024
Article

Data from a phase 3b trial support a supplemental new drug application in China for savolitinib in previously treated non–small cell lung cancer with MET exon 14 alterations.